Ko Kwan Soo, Song Jae-Hoon, Lee Mi Young, Park Sulhee, Kwon Ki Tae, Heo Sang Taek, Ryu Seong Yeol, Oh Won Sup, Peck Kyong Ran, Lee Nam Yong
Asian-Pacific Research Foundation for Infectious Diseases (ARFID), Seoul, South Korea.
Diagn Microbiol Infect Dis. 2006 Aug;55(4):337-41. doi: 10.1016/j.diagmicrobio.2006.02.001. Epub 2006 May 2.
In vitro activities of tigecycline were compared with 15 other comparator agents against recent clinical isolates of respiratory pathogens (623 Streptococcus pneumoniae, 105 Staphylococcus aureus, 92 Klebsiella pneumoniae, and 84 Haemophilus influenzae isolates) collected from 11 Asian countries. All isolates of S. pneumoniae from Asian countries were susceptible to tigecycline regardless of penicillin susceptibility with MIC90 of <or=0.06 mg/L. Both methicillin-resistant and methicillin-susceptible S. aureus isolates were susceptible to tigecycline with very low MIC90 values (0.25 and 0.12 mg/L, respectively). Tigecycline was also active against K. pneumoniae (98.9% susceptible; MIC50, 1 mg/L; MIC90, 2 mg/L) including 10 extended-spectrum beta-lactamase-producing isolates and H. influenzae (100% susceptible; MIC50 and MIC90, 0.12 mg/L) from Korea. Data confirmed that tigecycline has an excellent in vitro activity against drug-resistant clinical isolates of respiratory pathogens from Asian countries.
将替加环素与其他15种对照药物的体外活性进行了比较，这些对照药物针对的是从11个亚洲国家收集的近期呼吸道病原体临床分离株（623株肺炎链球菌、105株金黄色葡萄球菌、92株肺炎克雷伯菌和84株流感嗜血杆菌分离株）。亚洲国家的所有肺炎链球菌分离株对替加环素均敏感，无论青霉素敏感性如何，其MIC90均≤0.06mg/L。耐甲氧西林和甲氧西林敏感的金黄色葡萄球菌分离株对替加环素均敏感，MIC90值极低（分别为0.25和0.12mg/L）。替加环素对肺炎克雷伯菌（98.9%敏感；MIC50为1mg/L；MIC90为2mg/L）也有活性，包括10株产超广谱β-内酰胺酶的分离株，对来自韩国的流感嗜血杆菌（100%敏感；MIC50和MIC90为0.12mg/L）也有活性。数据证实，替加环素对来自亚洲国家的呼吸道病原体耐药临床分离株具有优异的体外活性。
